Aurora Cannabis (NASDAQ:ACB), a key player in the global medical marijuana market, stands at a strategic crossroads. Pablo Zuanic, a seasoned marijuana stock analyst from Zuanic & Associates, has initiated coverage on stock with a neutral rating. The core of his analysis hinges on whether Aurora's push into international markets will bolster its future or accelerate its challenges.

Zuanic's report delivers actionable insights into Aurora's finances and strategy, equipping investors to interpret earnings, assess global market impacts and make informed decisions in a dynamic industry.

"ACB is among the two largest medical cannabis companies globally and...